A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
Fernando Valerio Pascua, Oscar Diaz, Rina Medina, Brian Contreras, Jeff Mistroff, Daniel Espinosa, Anupamjeet Sekhon, Diego Paz Handal, Estela Pineda, Miguel Vargas Pineda, Hector Pineda, Maribel Diaz, Anita S Lewis, Heike Hesse, Miriams T Castro Lainez, Mark L Stevens, Miguel Sierra- Hoffman, Sidney C Ontai, Vincent Vanburen
PLOS ONE, doi:10.1371/journal.pone.0245025
Purpose COVID-19 pandemic has multifaceted presentations with rising evidence of immune-mediated mechanisms underplay. We sought to explore the outcomes of severe COVID-19 patients treated with a multi-mechanism approach (MMA) in addition to standard-of-care (SC) versus patients who only received SC treatment.
Materials and methods Data were collected retrospectively for patients admitted to the intensive care unit (ICU). This observational cohort study was performed at five institutions, 3 in the United States and 2 in Honduras. Patients were stratified for MMA vs. SC treatment during ICU stay. MMA treatment consists of widely available medications started immediately upon hospitalization. These interventions target immunomodulation, anticoagulation, viral suppression, and oxygenation. Primary outcomes included in-hospital mortality and length of stay (LOS) for the index hospitalization and were measured using logistic regression.
References
Alam, Hobbelink, Van Tienhoven, Van De Ven, Jansma et al., The impact of the use of the Early Warning Score (EWS) on patient outcomes: a systematic review, Resuscitation,
doi:10.1016/j.resuscitation.2014.01.013
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19-Preliminary Report, N Engl J Med
Chao, Woo, Hospitals pushed to the brink in Wuhan: 'I just want to save his life, Wall Street Journal
Cummings, Baldwin, Abrams, Jacobson, Meyer et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet,
doi:10.1016/S0140-6736%2820%2931189-2
De Wit, Van Doremalen, Falzarano, Munster, SARS and MERS: recent insights into emerging coronaviruses, Nat Rev Microbiol,
doi:10.1038/nrmicro.2016.81
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., GRECCO-19 investigators. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13136
Despres, Brunin, Berthier, Pili-Floury, Besch, Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients, Crit Care,
doi:10.1186/s13054-020-03001-6
Edgar, Najmabadi, Platoff, Texas hospitals are running out of drugs, beds, ventilators and even staff, Texas Tribune
Elharrar, Trigui, Dols, Touchon, Martinez et al., Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure, JAMA,
doi:10.1001/jama.2020.8255
Finkelsztein, Jones, Ma, Pabo ´n, Delgado et al., Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit, Crit Care,
doi:10.1186/s13054-017-1658-5
Fox, Akmatbekov, Harbert, Li, Brown et al., Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans, Lancet Respir Med,
doi:10.1016/S2213-2600%2820%2930243-5
Helms, Tacquard, Severac, Leonard-Lorant, Ohana et al., High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med,
doi:10.1007/s00134-020-06062-x
Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study, EClinicalMedicine,
doi:10.1016/j.eclinm.2020.100418
Sanche, Lin, Xu, Romero-Severson, Hengartner et al., High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2, Emerg Infect Dis,
doi:10.3201/eid2607.200282
Semple, In some nations, coronavirus is only one of many outbreaks
Soy, Keser, ¨ndu ¨z, Tabak, ¨ndu ¨z et al., Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment, Clin Rheumatol,
doi:10.1007/s10067-020-05190-5
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost,
doi:10.1111/jth.14817
Toniati, Piva, Cattalini, Garrafa, Regola et al., Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy, Autoimmun Rev,
doi:10.1016/j.autrev.2020.102568
Valerio Pascua, Diaz, Medina, Contreras, Mistroff et al., Project administration: Fernando Valerio Pascua
Valerio Pascua, Diaz, Medina, Contreras, Mistroff et al., Vincent
Villar, Confalonieri, Pastores, Meduri, Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019, Crit Care Explor
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet,
doi:10.1016/S0140-6736%2820%2931022-9
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736%2820%2930566-3